ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2024 CONCORD, MA, 29 May 2024 — ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive a functional cure for Hepatitis B, announced today that two abstracts will be [...]
ClearB Therapeutics Announces First Patient Dosed in a Phase 1b First in Human Study of CLB-3000 and a Presentation at AASLD 2023 of Preclinical data both for the Treatment of Chronic Hepatitis B Infection October 12, 2023 07:00 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, [...]
ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2023 June 20, 2023 09:17 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that [...]
ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 October 24, 2022 12:50 PM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, [...]
ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 June 15, 2022 09:16 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, [...]
Impact of various expression systems on efficacy of HBsAg therapeutic vaccines to achieve clearance in a mouse model of chronic hepatitis B ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract titled “Impact [...]
June 21, 2021 ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021 CONCORD, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract [...]
A recent paper by Fanning et al. in Nature Reviews Drug Discovery provides a very useful critical review of the recent literature that describes the rationale for curative therapies and the resulting compounds that are being tested in clinical trials for hepatitis B. To access this paper click here.
In July, 2019 the WHO published their progress report on three aligned global health sector strategies on HIV, viral hepatitis and sexually transmitted infections. These strategies were endorsed in 2016 at the 69th World Health Assembly by WHO Member States to guide actions over the period of 2016-2021 towards eliminating these diseases by 2030.
The WHO maintains a comprehensive list of compelling facts highlighting the global burden of hepatitis B.